Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease

American Journal of Hematology

Volumn 90, Issue 7, 2015, Pages 592-597

  Elstein, Deborah ^a   Mehta, Atul ^b,c   Hughes, Derralynn A ^b,c   Giraldo, Pilar ^d,e   Charrow, Joel ^f   Smith, Laurie ^g   Shankar, Suma P ^h   Hangartner, Thomas N ⁱ   Kunes, Yune ^j   Wang, Nan ^k   Crombez, Eric ^l   Zimran, Ari ^a  

^a HEBREW UNIVERSITY   (Israel)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f CHILDREN'S MEMORIAL HOSPITAL   (United States)

^g CHILDREN S MERCY HOSPITAL   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Wright State University   (United States)

^j SHIRE   (United States)

^k Biostatistics and Statistical Programming Department   (United States)

^l Shire   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHITOTRIOSIDASE; HEMOGLOBIN; IMIGLUCERASE; VELAGLUCERASE ALFA; BETA CHEMOKINE; BETA N ACETYLHEXOSAMINIDASE; CCL18 PROTEIN, HUMAN; GLUCOSYLCERAMIDASE; IMMUNOGLOBULIN G; VELAGLUCERASE ALFA, HUMAN;

ADOLESCENT; ADULT; AGED; ALLERGIC REACTION; ANTIBODY BLOOD LEVEL; ARTICLE; BONE DENSITY; BONE PAIN; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; ENZYME ACTIVITY; ENZYME REPLACEMENT; FATIGUE; FEMALE; GAUCHER DISEASE; HEMATOMA; HEMOGLOBIN DETERMINATION; HUMAN; IMMUNOGENICITY; INFUSION RELATED REACTION; LIVER WEIGHT; LONG TERM CARE; MALE; OLIGOHYDRAMNIOS; OPEN STUDY; PRIORITY JOURNAL; SPLEEN; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; LIVER; METABOLISM; MIDDLE AGED; ORGAN SIZE; PATHOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BONE DENSITY; CHEMOKINES, CC; CHILD; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; ENZYME REPLACEMENT THERAPY; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HEMOGLOBINS; HEXOSAMINIDASES; HUMANS; IMMUNOGLOBULIN G; LIVER; MALE; MIDDLE AGED; ORGAN SIZE; PLATELET COUNT; PROSPECTIVE STUDIES; SPLEEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84931828515     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24007     Document Type: Article

References (20)

1. Zimran A, Elstein D. Lipid storage diseases. In: Lichtman MA, Kipps T, Seligsohn U, Kaushansky K, Prchal JT, editors. Williams Hematology. New York: McGraw-Hill; 2010. pp 1065-1071.
2. Mistry PK, Zimran A. Type 1 Gaucher disease - clinical features. In: Futerman AH, Zimran A, editors. Gaucher disease. Boca Raton, FL: Taylor & Francis Group; 2007. pp 155-173.
3. Shire Human Genetic Therapies, Inc. VPRIV™: Highlights of prescribing information. 2010. Accessed June 9, 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022575lbl.pdf
4. Genzyme Corporation. CEREZYME® (imiglucerase for injection). 2005. Accessed June 14, 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20367s066lbl.pdf
5. Brumshtein B, Salinas P, Peterson B, et al. Characterization of gene-activated human acid-beta-glucosidase: Crystal structure, glycan composition, and internalization into macrophages. Glycobiology 2010;20:24-32.
6. Zimran A, Pastores GM, Tylki-Szymanska A, et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol 2013;88:172-178.
7. Ben Turkia H, Gonzalez DE, Barton NW, et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol 2013;88:179-184.
8. Gonzalez DE, Ben Turkia H, Lukina EA, et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, phase 3 study. Am J Hematol 2013;88:166-171.
9. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41:4-14.
10. Séllos-Moura M, Barzegar S, Pan L, et al. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease. J Immunol Methods 2011;373:45-53.
11. Hangartner TN. A study of the long-term precision of dual-energy X-ray absorptiometry bone densitometers and implications for the validity of the least-significant-change calculation. Osteoporos Int 2007;18:513-523.
12. Genant HK, Grampp S, Gluer CC, et al. Universal standardization for dual X-ray absorptiometry: Patient and phantom cross-calibration results. J Bone Miner Res 1994;9:1503-1514.
13. Hanson J. Standardization of femur BMD. J Bone Miner Res 1997;12:1316-1317.
14. Schousboe JT, Shepherd JA, Bilezikian JP, et al. Executive Summary of the 2013 International Society for Clinical Densitometry Position Development Conference on Bone Densitometry. J Clin Densitom 2013;16:455-466.
15. Schoonhoven A, Rudensky B, Elstein D, et al. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta 2007;381:136-139.
16. Boot RG, Renkema GH, Verhoek M, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem 1998;273:25680-25685.
17. Elstein D, Hughes D, Goker-Alpan O, et al. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease. J Obstet Gynaecol Res 2014;40:968-975.
18. Boot RG, Verhoek M, de Fost M, et al. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood 2004;103:33-39.
19. Hollak CE, van Weely S, van Oers MH, et al. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-1292.
20. Pastores GM, Rosenbloom B, Weinreb N, et al. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: Safety and tolerability. Genet Med 2014;16:359-366.